{"id":"bemegride","rwe":[],"tags":[{"label":"bemegride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"R07AB05","category":"atc"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Stimulants","category":"pharmacology"},{"label":"Convulsants","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"etimid","offLabel":[],"synonyms":["bemegride","bemegrid","etimid","eukraton","megimid","megibal","megimide","methetharimide","mikedimide","zentraleptin"],"timeline":[],"brandName":"Etimid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bemegride","explanation":"Imagine your brain is a city with many different neighborhoods, each with its own unique function. Bemegride is like a loudspeaker that broadcasts a signal to the entire city, increasing the activity of the different neighborhoods and helping to restore balance to the brain's functions.","oneSentence":"Bemegride works by stimulating the central nervous system to increase the activity of neurotransmitters.","technicalDetail":"Bemegride is a central nervous system stimulant that acts as a GABA antagonist, increasing the release of excitatory neurotransmitters such as glutamate and aspartate, and decreasing the release of inhibitory neurotransmitters such as GABA."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3013","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEMEGRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:50:10.477579","biosimilars":[],"competitors":[{"drugName":"doxapram","drugSlug":"doxapram","fdaApproval":"1965-06-23","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"bemegride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxapram","brandName":"doxapram","genericName":"doxapram","approvalYear":"1965","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001380","UNII":"57DQA39DO2","CHEBI":"CHEBI:92269","INN_ID":"511","UMLSCUI":"C0004960","ChEMBL_ID":"CHEMBL1214192","KEGG_DRUG":"D01957","DRUGBANK_ID":"DB13740","PUBCHEM_CID":"2310","MESH_DESCRIPTOR_UI":"D001534"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":287,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"R07AB05","allCodes":["R07AB05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etimid (Bemegride) is a small molecule drug in the bemegride class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unclear, but it is used to treat certain conditions. The commercial status of Etimid is unknown, and it is not clear if it is patented or available as a generic medication. Key safety considerations are not well-documented. Further research is needed to fully understand Etimid's properties and uses.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}